Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 10, 2004, Pages 1755-1760

  Brewer Jr , H Bryan ^a   Remaley, Alan T ^a   Neufeld, Edward B ^a   Basso, Federica ^a   Joyce, Charles ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

ABCA1 transporter; apoA I; Cholesterol; Cholesteryl ester transfer protein; Cholesteryl ester transfer protein inhibitor

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MILANO; APOLIPOPROTEIN B; ATORVASTATIN; CELL ADHESION MOLECULE; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; J 77705; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEIN INHIBITOR; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL LEVEL; CELL TRANSPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMPLEX FORMATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER CLEARANCE; LONG TERM CARE; MONOCYTE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROCESS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SHORT SURVEY; SIDE EFFECT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL;

EID: 5344253917     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000142804.27420.5b     Document Type: Short Survey

References (73)

1. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
2. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
3. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol. 1992;2:23-28.
4. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-167.
5. Assmann G, von Eckardstein A, Brewer HBJ. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill; 2001:2937-2980.
6. Brooks-Wilson A, Marcil M, Clee SM, Zhang L-H, Roomp K, van Dam M, Yui L, Brewer C, Collins JA, Molhuizen HOF, Loubser O, Ouelette BFF, Fichter K, Ashbourne-Excoffon KJD, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJP, Genest JJ, Jr, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 1999;22:336-345.
7. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminiski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 1999;22:347-351.
8. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HBJ, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the ATP binding cassette transporter 1 (ABC1) gene. Nature Genet. 1999;22:352-355.
9. Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, Peterson KM, Koch C, Arnould I, Prades C, Duverger N, Funke H, Assmann G, Dinger M, Dean M, Chimini G, Santamarina-Fojo S, Fredrickson DS, Denefle P, Brewer HBJ. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA. 1999;96:12685-12690.
10. Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, Fitzgerald MG, Yasek-McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown RH, Jr, Gu JZ. Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds. J Lipid Res. 2000;41:433-441.
11. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-R31.
12. Schaefer EJ, Blum CB, Levy RI, Jenkins LL, Alaupovic P, Foster DM, Brewer HBJ. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med. 1978;299:905-910.
13. Santamarina-Fojo S, Peterson K, Knapper C, Qiu Y, Freeman L, Cheng J-F, Osorio J, Remaley A, Yang XP, Haudenschild C, Prades C, Chimini G, Blackmon E, Francois T, Duverger N, Rubin EM, Rosier M, Denefle P, Fredrickson DS, Brewer HBJ. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci USA. 2000;97:7987-7992.
14. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α. Proc Natl Acad Sci U S A. 2000;97:12097-12102.
15. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 2000;274:794-802.
16. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-28245.
17. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in choleterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
18. Yang XP, Freeman LA, Knapper CL, Amar MJA, Remaley A, Brewer HBJ, Santamarina-Fojo S. The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. J Lipid Res. 2002;43:297-306.
19. Oram JF, Vaughan AM. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr Opin Lipidol. 2000;11:253-260.
20. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HBJ. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun. 2001;280:818-823.
21. Assmann G, Brewer HBJ. A molecular model of high density lipoproteins. Proc Natl Acad Sci U S A. 1974;71:1534-1538.
22. Anantharamaiah GM, Brouillette CG, Engler JA, De Loof H, Venkatachalapathi YV, Boogaerts J, Segrest JP. Role of amphipathic helixes in HDL structure/function. Adv Exp Med Biol. 1991;285:131-140.
23. Brewer HBJ, Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ. The amino acid sequence of human ApoA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 1978;80:623-630.
24. Brewer HBJ, Lux SE, Ronan R, John KM. Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc Natl Acad Sci U S A. 1972;69:1304-1308.
25. Hospattankar AV, Brewer HBJ, Ronan R, Fairwell T. Amino acid sequence of human plasma apolipoprotein C-III from normolipidemic subjects. FEBS Lett. 1986;197:67-73.
26. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Hough G, Wagner A, Nakamura K, Garber DW, Datta G, Segrest JP, Hama S, Fogelman AM. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2003;4:1100-1104.
27. Neufeld EB, Remaley AT, Demosky SJ, Jr., Stonik JA, Cooney AM, Comly M, Dwyer NK, Zhang M, Blanchette-Mackie J, Santamarina-Fojo S, Brewer HBJ. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem. 2001;276:27584-27590.
28. Neufeld TB, Stonik JA, Demosky SJ, Knapper CL, Combs CA, Cooney A, Dwyer N, Blanchette-Mackie J, Remaley AT, Santamarina-Fojo S, Brewer HB, Jr. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem. 2004;279:15571-15578.
29. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem. 2002;277:22426-22429.
30. Martinez LO, Angerholm-Larsen B, Wang N, Chen W, Tall AR. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem. 2003;278:37368-37374. Ref Type: Abstract
31. Arakawa R, Hayashi M, Remaley AT, Brewer HB Jr, Yamauchi Y, Yokoyama S. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J Biol Chem. 2004;279:6217-6220.
32. Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, De la Llera-Moya M, Rothblat GH. Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol. 1999;10:329-339.
33. Yancey PG, Bortnick AE, Kellner-Weibel G, De la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol. 2003;23:712-719.
34. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
35. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem. 2002;278:3937-3947.
36. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001;1:155-161.
37. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285-288.
38. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld EB, Remaley AT, Brewer HBJ, Santamarina-Fojo S. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest. 2001;108:303-309.
39. Joyce C, Amar MJA, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, Hoyt RF, Jr., Neufeld ED, Remaley AT, Fredrickson DS, Brewer HBJ, Santamarina-Fojo S. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Nat Acad Sci. 2002;99:407-412.
40. Neufeld EB, Demosky SJ, Stonik JA, Combs C, Remaley AT, Duverger N, Santamarina-Fojo S, Brewer HB, Jr. The ABCA1 transporter functions on the basolateral surface of hepatocytes. Biochem Biophys Res Comm. 2002;297:974-979.
41. Haghpassand M, Bourassa PAK, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest. 2001;108:1315-1320.
42. Basso FP, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, Tansey T, Amar MJA, Fruchart-Najib J, Duverger N, Santamarina-Fojo S, Brewer HB, Jr. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL-cholesterol concentrations. J Lipid Res. 2003;44:296-302.
43. Schwartz CC, Berman M, Vlahcevic ZR, Halloran LG, Gregory DH, Swell L. Multicompartmental analysis of cholesterol metabolism in man: the hepatic bile acid and biliary cholesterol precursor sites. J Clin Invest. 1978;61:408-423.
44. Schwartz CC, Vlahcevic ZR, Berman M, Meadows JG, Nisman RM, Swell L. Central role of high density lipoprotein in plasma free cholesterol metabolism. J Clin Invest. 1982;70:105-116.
45. Schwartz CC, Vlahcevic ZR, Halloran LG, Swell L. An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile. Biochim Biophys Acta. 1981;663:143-162.
46. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thomb Vasc Biol. 2003;23:1732-1738.
47. Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998;9:211-219.
48. Huuskonen J, Oikkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis. 2001;155:269-281.
49. Pietinen P, Huttunen JK. Dietary determinants of plasma high-density lipoprotein cholesterol. Am Heart J. 1987;113:620-625.
50. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
51. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
52. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart JC, Houdebine LM, Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 1996;94:713-717.
53. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SJ, Haudenschild CC, Vaisman BL, Hoyt RF, Jr, Demosky SJ, Jr, Kauffman RD, Hazel CM, Marcovina SM, Brewer HBJ. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A. 1996;93:11448-11453.
54. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
55. Bodary PF, Eitzman DT, Shen Y, Westrick RJ, Lalwani ND, Drake SL, Dasseux J-L. Gene transfer of an ApoA-I mimetic peptide reduces atherosclerosis in mice. J Amer Col Cardiol. 2004;43:5(Suppl A):1064, 182.
56. Rader DJ, Schaefer JR, Lohse P, Ikewaki K, Thomas F, Harris WA, Zech LA, Dujovne CA, Brewer HBJ. Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism. 1993;42:1429-1434.
57. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594-598.
58. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon S, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
59. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med. 1998;27:659-667.
60. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol. 2000;11:589-596.
61. Barter PJ, Brewer HBJr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis. Arterioscler Thomb Vasc Biol. 2003;23:160-167.
62. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
63. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettery CL, Adar H, Hammond RA, Beattie DT, Callow AD, Marsh HC, Ryan US. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis. Arterioscler Thomb Vasc Biol. 2000;29:2106-2112.
64. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
65. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
66. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising High Density Lipoprotein in Humans through Inhibition of Cholesteryl Ester Transfer Protein: An initial multidose Study of Torcetrapib. Arter Thromb Vasc Biol. 2004;24:490-497.
67. Brousseau ME, Schaefer EJ, Wolfe ML, Bloeden LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
68. Yamashita S, Matsuzawa Y, Okazaki M, Kako H, Yasugi T, Akioka H, Hirano K, Tarui S. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis. 1988;70:7-12.
69. Sakai N, Matsuzawa Y, Hirano K, Yamashita S, Nozaki S, Ueyama Y, Kubo M, Tarui S. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb. 1991;11:71-79.
70. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H, Nagano M, Brewer HBJ. Delayed catabolism of high-density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 1993;92:1650-1658.
71. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, Nagano M, Nakamura H, Brewer HBJ, Rader DJ. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 1995;96:1573-1581.
72. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem (Tokyo). 1994;116:257-262.
73. Sakai N, Yamashita S, Hirano K, Ishigami M, Arai T, Kobayashi K, Funahashi T, Matsuzawa Y. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur J Clin Invest. 1995;25:332-339.